Wanyi Chen

Dr. Wanyi Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Journal of Fluorescence
Verified
Journal Article
Closed access
PDF file
JZJiao Zhang
Jiao Zhang
QYQinghua Yu
Qinghua Yu
WCWanyi Chen
Wanyi Chen

3 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PLPingPing Long
PingPing Long
SLSiyu Li
Siyu Li
LPLingyun Pan
Lingyun Pan
YWYuanqiang Wang
Yuanqiang Wang
WCWanyi Chen
Wanyi Chen
XWXiaoxiao Wang
Xiaoxiao Wang
Objective: As a novel drug formulation, antibody drug conjugates (ADCs) are widely used in various types of cancer. However, clinically, there is a lack of attention to the CVD produced by them, as well as a lack of research on the real-world situation. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to ensure its clinical safety application, we analyzed post-marketing data on antitumor ADCs to identify risk factors and drugs associated with the risk of cardiovascular events.Research design and methods: We used OpenVigil 2.1 to conduct a database query for adverse events (AEs) reported to the FAERS database between the time the drug was launched and the second quarter of 2023. Cardiovascular adverse events (AEs) were grouped into fourteen narrow categories using the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs), and the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for reporting the association between different drugs and cardiovascular disease (CVD) risk were calculated.Results: In the FAERS database, 1863 AEs associated with CVD we studied were identified in patients receiving ADC therapy. Most reports came from people aged ≥65, but a significant number of cases were found to be unknown. The number of patients with antibody-drug conjugates (ADCs)-related CVD cases aged <18 years, 18–64 years, and≥ 65 years was 52 (2.79%), 586 (31.45%), and 613 (32.90%), respectively. The proportion of female patients (834, 44.77%) was higher than that of male patients (752, 40.37%). Death (770 reports), disability (9 reports), Hospitalization initial or prolonged (407 reports), and life-threatening reactions (187 reports). Of the 770 deaths reported, 103 (31.7%) were associated with brentuximab vedotin, 10 (24.4%) with sacituzumab govitecan, 22 (19.3%) with enfortumab vedotin, and 35 (34.7%) with trastuzumab emtansine.49 (41.2%) cases were associated with polatuzumab vedotin, 62 (29%) with trastuzumab deruxtecan, 423 (54.3%) with gemtuzumab ozogamicin, and 66 (38.8%) with inotuzumab ozogamicin. In a disproportionate number of SMQS, cardiac failure (n = 277) and embolic and thrombotic events, venous (n = 446) were the most frequently reported CVD-related AEs in ADCs.Conclusion: By mining the FAERS database, we provided relevant information on the association between ADC use and cardiovascular-associated AEs. ADCs were associated with increased cardiovascular toxicity, deserving distinct monitoring and appropriate management. Further research is needed to confirm these findings and assess causality.

10 July 2025 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
SLSiyu Li
Siyu Li
WLWenrui Li
Wenrui Li
MCMengfei Cheng
Mengfei Cheng
XWXiaoxiao Wang
Xiaoxiao Wang
WCWanyi Chen
Wanyi Chen
Background: Anthracyclines are cornerstone chemotherapeutics, but cardiotoxicity limits their use. Objective: This study aims to evaluate the efficacy of various drugs in preventing and treating anthracycline-induced cardiotoxicity (AIC). Methods: We conducted an extensive search across seven databases to identify randomized controlled trials (RCTs) pertinent to the prevention and treatment of AIC with medications. Subsequently, a Bayesian Model-based network meta-analysis was performed in the R 4.4.0. Results: A total of 128 RCTs involving 10,431 cancer patients treated with anthracyclines and 78 drug regimens were included in this study. The network meta-analysis results showed that, compared with patients who did not receive cardioprotective drugs, those treated with Calcium Dibutyryladenosine Cyclophosphate (Mean Difference [95% Credible Interval], 8.760 [0.5917, 16.92]), Carvedilol (4.024 [0.5372, 7.656]), Carvedilol + Candesartan (7.934 [3.159, 12.91]), Compound Salvia Miltiorrhiza + Levocarnitine (9.087 [0.9160, 17.25]), Dexrazoxane (5.066 [2.589, 7.540]), Dexrazoxane + Cinobufacini (11.61 [4.590, 18.70]), Dexrazoxane + Shenqi Fuzheng (13.05 [4.640, 21.40]), Nicorandil (14.24 [5.122, 23.31]), Qiliqiangxin (11.38 [2.826, 19.91]), and Xinmai Long (6.371 [1.735, 11.02]) experienced less decrease in LVEF after chemotherapy. The SUCRA ranking results indicated that the most effective treatment option for preserving LVEF was Nicorandil (SUCRA 91.76%). Conclusion: Apart from Dexrazoxane, Carvedilol, a β-blocker, also appears to show significant potential in preventing AIC. Furthermore, our results indicate that there is insufficient evidence to support the beneficial effects of statins, Sildenafil, Ivabradine, Levocarnitine, N-acetylcysteine, Glutathione, Coenzyme Q10, Vitamin E, and Vitamin C in preventing LVEF decline and exerting a positive effect on the prevention of AIC.

22 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CLChunming Li
Chunming Li
TZTengyue Zhao
Tengyue Zhao
LLLixian Li
Lixian Li
GHGang Xiao Hu
Gang Xiao Hu
CLChao Li
Chao Li
YHYurong Hu
Yurong Hu
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.

15 September 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YGYudi Gao
Yudi Gao
HLHong Lin
Hong Lin
TTTiantian Tang
Tiantian Tang
YWYuanqiang Wang
Yuanqiang Wang
WCWanyi Chen
Wanyi Chen
LLLixian Li
Lixian Li

29 October 2024 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LPLingyun Pan
Lingyun Pan
LMLi Mu
Li Mu
HLHaike Lei
Haike Lei
SMSiwei Miao
Siwei Miao
XHXiaogang Hu
Xiaogang Hu
XWXiaoxiao Wang
Xiaoxiao Wang